Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma
Open accessThe DOI matches its Crossref record; 61 of the 64 references it cites were found in a registry or an index.
Abstract
Malignant mesothelioma is an aggressive malignancy related to asbestos and erionite exposure. AP-1 transcriptional activity and the NF-κB signaling pathway have been linked to mesothelial cell transformation and tumor progression. HGF and c-Met are highly expressed in mesotheliomas. Phosphoinositide 3-kinase, AKT, and the downstream mTOR are involved in cell growth and survival, and they are often found to be activated in mesothelioma. p16(INK4a) and p14(ARF) are frequently inactivated in human mesothelioma, and ∼50% of mesotheliomas contain the NF2 mutation. Molecular therapies aimed at interfering with these pathways have not improved the dismal prognosis of mesothelioma, except possibly for a small subset of patients who benefit from certain therapies. Recent studies have shown the importance of asbestos-induced inflammation in the initiation and growth of mesothelioma, and HMGB1 and Nalp3 inflammasome have been identified as key initiators of this process. Asbestos induces cell necrosis, causing the release of HMGB1, which in turn may activate Nalp3 inflammasome, a process that is enhanced by asbestos-induced production of reactive oxygen species. HMGB1 and Nalp3 induce proinflammatory responses and lead to interleukin-1β and TNF-α secretion and NF-κB activity, thereby promoting cell survival and tumor growth. Novel strategies that interfere with asbestos- and erionite-mediated inflammation might prevent or delay the onset of mesothelioma in high-risk cohorts, including genetically predisposed individuals, and/or inhibit tumor growth. The very recent discovery that germline BAP1 mutations cause a new cancer syndrome characterized by mesothelioma, uveal melanoma, and melanocytic tumors provides researchers with a novel target for prevention and early detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Asbestos induces carcinogenesis by directly interfering with mitotic spindle formation and by inducing chronic inflammation [2e4] with the production of cytokines and reactive oxygen species (ROS) by activated macrophages.ROS are also generated by the iron contained in asbestos fibers [5].”
From Germline Mutations in DNA Repair Genes Predispose Asbestos-Exposed Patients to Malignant Pleural Mesothelioma (2017) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794 · cited 1×
“DAMP and a key mediator of inflammation (37) that, in turn, can trigger activation of Nalp3”
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658 · cited 1×
“Nalp3-deficient mice exhibited decreased pulmonary pathology in response to silica and asbestos exposure compared to wild-type controls (38).”
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436 · cited 1×
“and endogenous damage-associated molecular patterns (DAMPs) (34, 35).”
Franchi, L., Eigenbrod, T., Muñoz-Planillo, R., & Nuñez, G. (2009) · Nature Immunology · doi:10.1038/ni.1703 · Cited by 1,834
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497 · cited 1×
“Accordingly, daily treatment with aspirin for 5 or more years reduced tumor burden in several common malignancies (55).”
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462 · cited 1×
“In addition to familiar cases, BAP1 somatic mutations have been identified in 25% of sporadic mesotheliomas (10, 12) and in 84% of metastasizing uveal melanomas (13) but appear to be relatively rare in other cancers (14, 15).”
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076 · cited 5×
“Individuals with heterozygous BAP1 germline mutations are affected by a novel cancer syndrome characterized by very high risk of developing mesothelioma, uveal melanoma, and possibly additional cancers (10).”
InfluentialSelf-citationFubini, B., & Hubbard, A. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00149-7 · Cited by 935 · cited 1×
“Other minerals, such as crystalline silica, also elicit ROS and iNOS production from lung macrophages but do not cause mesothelioma (20).”
The Nalp3 inflammasome is essential for the development of silicosis
Cassel, S. L., Eisenbarth, S. C., Iyer, S. S., Sadler, J. J., Colegio, O. R., Tephly, L. A., Carter, A. B., Rothman, P. B., Flavell, R. A., & Sutterwala, F. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803933105 · Cited by 907
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome
Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., & Dixit, V. M. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200903124 · Cited by 820
Cited by
Carbone, M., Yang, H., Pass, H. I., Krausz, T., Testa, J. R., & Gaudino, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3459 · Cited by 590
Self-citationMesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Self-citationNovel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324
The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases
Sayan, M., & Mossman, B. T. (2015) · Particle and Fibre Toxicology · doi:10.1186/s12989-016-0162-4 · Cited by 296
HMGB1 as a therapeutic target in disease
Xue, J., Suarez, J. S., Minaai, M., Li, S., Gaudino, G., Pass, H. I., Carbone, M., & Yang, H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30125 · Cited by 294
Self-citation
Metadata
- Authors
- Carbone, M., & Yang, H.
- Affiliations
- University of Hawaiʻi at Mānoa (US)
- Corresponding author
- Yang, Haining
- Venue
- Clinical Cancer Research
- Published
- 2012-01-31
- Volume
- 18
- Issue
- 3
- Pages
- 598-604
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3291331
- OpenAlex
- W2119826693
- Cited by
- 229
- References
- 64
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 14 · 2023: 15 · 2022: 17 · 2021: 23 · 2020: 19 · 2019: 13 · 2018: 8 · 2017: 21 · 2016: 14 · 2015: 21 · 2014: 20 · 2013: 19 · 2012: 7
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p01ca114047-05)
- National Cancer Institute (R01CA160715, P01CA-114047)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- malignant mesothelioma, asbestos, erionite, carcinogenesis, AP-1 transcription, NF-κB signaling, PI3K/AKT/mTOR pathway, p16INK4a, p14ARF, NF2 mutation, HMGB1, NLRP3 inflammasome, reactive oxygen species, IL-1β, TNF-α, BAP1 mutation, uveal melanoma, melanocytic tumors, molecular therapy
- MeSH terms
- Asbestos, Cell Transformation, Neoplastic, Humans, Mesothelioma, Zeolites
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-2259
- The paper
- Carbone, M., & Yang, H. (2012). Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-2259
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.